Through the partnership, Zephyr will train its Insights predictive analysis tool with MedStar’s datasets. Initially, the partnership will focus on Type 2 diabetes, according to a Nov. 4 Zephyr news release.
“We are laser-focused on delivering results that improve the timeliness of Type 2 diabetes interventions and decrease devastating adverse health outcomes commonly associated with the chronic condition, such as end-stage chronic kidney disease, dialysis, foot ulcers, and amputations,” Zephyr co-founder and Chair Grant Verstandig said.
